AKT1 and ulcerative colitis: SOAR's integrative approach toward drug discovery revealed sirolimus and trichostatin A as potential anticancer agents targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin growth and proliferation pathway and identified Janus kinase/signal transducers and activators of transcription inhibitors for ulcerative colitis treatment.